200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Stockholders Approve Madrigal Pharmaceuticals 2026 Stock Plan
Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Board Reclassification of Directors at Madrigal Pharmaceuticals
Reports Fourth-Quarter and Full-Year 2025 Financial Results
First Amendment to Research Agreement with Roche Signed by Madrigal
Rita Thakkar Appointed Senior VP and Chief Accounting Officer
Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence